Pneumagen announced the initiation of a Phase 2 challenge study of its Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, which is the company is developing as a universal treatment for influenza, RSV, and COVID-19. The Phase 2 trial is expected to enroll up to 100 subjects who will receive one of two dose levels of Neumifil or a placebo nasal spray … [Read more...] about Pneumagen initiates Phase 2 challenge study of Neumifil nasal spray against flu
News
Positive Phase 3 results for Bharat Biotech’s BBV154 intranasal COVID-19 vaccine
According to Bharat Biotech, two recently completed Phase 3 trials of its BBV154 intranasal COVID-19 vaccine demonstrated the safety and tolerability of the recombinant replication-deficient adenovirus vectored vaccine and as well as its ability to elicit an immune response. One of the trials enrolled approximately 3100 subjects who received either two doses of BBV154 … [Read more...] about Positive Phase 3 results for Bharat Biotech’s BBV154 intranasal COVID-19 vaccine
HDT Bio Gets $1.8 million for US Army for development of antiviral nasal spray
HDT Bio announced that it has received a grant of ~$1.8 million from the US Army Medical Research Acquisition Activity for development of the company's HDT-201 RNA-based nasal spray for the prevention and treatment of viral infections. The company said that the funding will support pre-clinical safety and potency studies, with clinical trials anticipated to begin in … [Read more...] about HDT Bio Gets $1.8 million for US Army for development of antiviral nasal spray
Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans
Canadian biotech Ceapro announced the expansion of an existing collaboration with McMaster University for development of inhaled yeast beta glucans for the prevention and treatment of lung fibrosis caused by COVID-19. According to Ceapro, the team has already successfully created inhalable yeast beta glucan particles via PGX and now plans to optimize delivery and … [Read more...] about Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans
Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation
Harm Reduction Therapeutics announced that it has signed a commercial supply agreement for its RiVive (HRT001) intranasal naloxone after the FDA granted Fast Track designation to the nasal spray, which is in development as a low cost OTC product for the reversal of opioid overdose. HRT did not name the company it contracted with but said that RiVive would be … [Read more...] about Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation
Aridis says that its AR-701 inhaled mAb cocktail is effective against SARS-CoV-2 in macaques
Aridis Pharmaceuticals said that its AR-701 inhaled monoclonal antibody cocktail effectively reduced viral load in rhesus macaques infected with SARS-CoV-2 and protected against lung disease in those animals over a 5-day period. The company received $1.9 million from the Bill & Melinda Gates Foundation in January 2022 for preclinical development of its inhaled … [Read more...] about Aridis says that its AR-701 inhaled mAb cocktail is effective against SARS-CoV-2 in macaques
Opiant gets addition $2.1 million from BARDA for OPNT003
Opiant Pharmaceuticals said that it has received an additional $2.1 million from the US Biomedical Advanced Research and Development Authority (BARDA) to support regulatory activities related to its OPNT003 intranasal nalmefene for the treatment of opioid overdose. BARDA had already provided an additional $2.2 million for OPNT003 earlier this year, and the total … [Read more...] about Opiant gets addition $2.1 million from BARDA for OPNT003
Verona announces that Phase 3 trial of nebulized ensifentrine for COPD met its primary endpoint
Verona Pharma said that the Phase 3 ENHANCE-2 trial of nebulized ensifentrine for treatment of COPD met its primary endpoint, with an average change from baseline in FEV1 AUC, 0-12 hours post dose, of 94 ml at week 12. In addition, a number of secondary endpoints were met, and for patients who got ensifentrine, the rate of exacerbations was reduced by 42% over 24 … [Read more...] about Verona announces that Phase 3 trial of nebulized ensifentrine for COPD met its primary endpoint
Innovate UK awards £1 million grant to Acu-Flow for development of Nebu-Flow technology
The University of Glasgow announced that Innovate UK has awarded a university spinout, Acu-Flow, £1 million for development of the company's Nebu-Flow surface acoustic wave nebulizer technology. The University said that its researchers will work with Acu-Flow and the NIHR Devices for Dignity Med-tech Cooperative to have a working nebulizer ready for manufacturing … [Read more...] about Innovate UK awards £1 million grant to Acu-Flow for development of Nebu-Flow technology
Aptar Pharma acquires rights to Pharmaxis’ Orbital DPI
Aptar Pharma announced that it has acquired worldwide rights to Pharmaxis’ high payload Orbital dry powder inhaler. In August 2021, the company said that it had acquired an option to purchase the rights to the Orbital DPI and that it had 12 months to decide whether or not to exercise that option. The Orbital inhaler can handle total doses up to 400 mg and was … [Read more...] about Aptar Pharma acquires rights to Pharmaxis’ Orbital DPI